Atlas Trials

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Clinical trial NCT03109301 · WITHDRAWN

Trial details

NCT number
NCT03109301
Sponsor
National Cancer Institute (NCI)
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Neoplasms, Nerve TissueNeurofibromatosis 1Heredodegenerative Disorders, Nervous SystemPeripheral Nervous System Diseases
Start date
2017-04-07
Primary completion
2019-03-27
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.